生肌活血方外用治疗阿帕替尼引起的手足综合征的临床效果

Analysis on the clinical efficacy of Shengji Huoxue Prescription on hand-foot syndrome caused by apatinib

目的探讨生肌活血方外用治疗阿帕替尼引起手足综合征的临床效果。方法选取2017年11月至2019年10月我院收治的因阿帕替尼治疗引发手足综合征的肿瘤患者164例作为研究对象,采用随机数字表法将其分为试验组和对照组,每组各82例。对照组患者予以尿素霜涂抹患处进行治疗,给药剂量10 g/次。试验组患者则采用生肌活血方外用治疗。以治疗28 d为1个疗程,治疗1个疗程后,比较两组患者治疗前后的手足综合征分级和皮肤病生活质量指数的变化,统计其临床疗效。结果治疗后,两组患者的HFS分级情况较治疗前均有所好转(P<0.05),且治疗后试验组患者的HFS分级的情况优于对照组,差异有统计学意义(P<0.05)。试验组患者治疗的总有效率为80.49%,高于对照组的56.10%,差异有统计学意义(P<0.05)。治疗后,两组的皮肤病生活质量指数(DLQI)较治疗前均有明显降低(P<0.01),且试验组明显低于对照组,差异有统计学意义(P<0.01)。结论针对阿帕替尼引起手足综合征,采用生肌活血方外用治疗,能起到较好的临床效果,促进患者症状的改善。

Objective To investigate and analyze the clinical efficacy of Shengji Huoxue Prescription on hand-foot syndrome(HFS)caused by apatinib.Methods A total of 164 cancer patients with HFS caused by apatinib admitted to our hospital from November 2017 to October 2019 were selected as the study objects,and they were divided into the experimental group and the control group,with 82 cases in each group according to the random number table method.Patients in the control group were treated with urea cream applied to the affected area with a dose of 10 g/time,while those in the experimental group were treated with Shengji Huoxue Prescription for external treatment.28 days were taken as a course of treatment.After a course of treatment,the changes of HFS classification and quality of life(QoL)index of patients with skin disease before and after treatment were compared between the two groups,and the clinical efficacy was counted.Results After treatment,the HFS classification of patients in both groups were improved more significantly than that before treatment(P<0.05).And after treatment,the HFS classification of patients in the experimental group was better than that in the control group,with statistically significant difference(P<0.05).The total effective rate in the experimental group was 80.49%,which was higher than that of 56.10%in the control group,with statistically significant difference(P<0.05).After treatment,the dermatology life quality index(DLQI)scores between the two group,were significantly lower than those before treatment(P<0.01).Meanwhile,the DLQI score in the experimental group was significantly lower than that in the control group,with statistically significant difference(P<0.01).Conclusion In view of the HFS caused by apatinib,the external application of Shengji Huoxue Prescription can achieve better clinical efficacy and promote the improvement of patients′symptoms.